NCT07435285 Analysis of Inflammatory Biomarker Changes in Dry Blood Spot Versus Venous Blood Samples
| NCT ID | NCT07435285 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | Inflammation |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-01-15 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see whether dried blood spot (DBS) samples can measure inflammatory biomarkers as accurately as venous blood samples. Investigators will be measuring inflammatory biomarkers changes obtained in DBS compared with paired venous blood samples following a controlled physiological stressor (i.e. after a vaccine or other planned event that can cause a temporary rise in inflammation). These findings will help understand whether DBS can be a reliable alternative to traditional blood draws in future research and healthcare.
Eligibility Criteria
Inclusion Criteria: * Men or women aged ≥18 years, who are planning to receive a seasonal vaccine OR have a scheduled acute stressor\*. Exclusion Criteria: * Any infectious symptoms (fever, cough, rhinorrhea, sore throat, diarrhea, loss of smell or taste) within the previous 7 days * Any self-reported active/recent use of cocaine, injection drugs, or amphetamines * Acute worsening of a known chronic health condition within the previous 30 days (e.g., of IBD, COPD, asthma, rheumatologic disease) * Known severe allergy or intolerance to the planned vaccine * Contraindication to the vaccine received, if applicable \*List of possible scheduled acute stressors include: * Hard exercise (incl. 10km run or longer, high-intensity interval training, or comparable endurance activity) * Social event with moderate alcohol consumption * Planned change in medication dose and/or frequency of use * Onset of menstruation (day 1) * Other pre-planned stressors expected to elicit an inflammatory response
Contact & Investigator
Emily G. McDonald, MD MSc
PRINCIPAL INVESTIGATOR
McGill University Health Centre/Research Institute of the McGill University Health Centre
Frequently Asked Questions
Who can join the NCT07435285 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07435285 currently recruiting?
Yes, NCT07435285 is actively recruiting participants. Contact the research team at cpau.med@mcgill.ca for enrollment information.
Where is the NCT07435285 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT07435285 clinical trial?
NCT07435285 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The principal investigator is Emily G. McDonald, MD MSc at McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 50 participants.